Skip to NavigationSkip to content

Takeda to sell another non-core portfolio for $260 million to Cheplapharm

Published on 08/09/20 at 11:40am

Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an upfront payment of $562 million.

The portfolio of products, sold primarily in Europe and Canada, include therapies in the anti-inflammatory and cardiovascular/metabolic spaces which generated $260 million in sales for Takeda throughout 2019’s fiscal year.

The Japanese pharma firm is jettisoning the products as they no longer fit within its five key therapeutic areas of gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.

“Today’s announcement allows Takeda to continue to be patient-focused as we streamline and optimise our portfolio according to our global long-term strategy,” remarked Costa Saroukos, Chief Financial Officer at Takeda. “While the trusted products included in the sale address key patient needs in these countries, they are outside of our core business areas of focus. We are confident that Cheplapharm is the right partner to ensure patients continue to have access to these products.”

The decision follows the sale last month of the company’s Consumer Healthcare Company to global investment firm Blackstone for around £2.3 billion, the sale of a non-core over-the-counter (OTC) portfolio of drugs sold in the Asia Pacific to Celltrion for $278 million in June, and the sale in April of another OTC portfolio in Europe to Orifarm for up to $670 million. The moves represent Takeda’s attempts to balance the books following its mammoth acquisition of Shire in 2018 for $62 billion.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches